Pharmacological inhibition of the psychiatric risk factor FKBP51 has anxiolytic properties

Journal of Neuroscience

Volumn 35, Issue 24, 2015, Pages 9007-9016

  Hartmann, Jakob ^a   Wagner, Klaus V ^a   Gaali, Steffen ^a   Kirschner, Alexander ^a   Kozany, Christian ^a   Rühter, Gerd ^b   Dedic, Nina ^a   Häusl, Alexander S ^a   Hoeijmakers, Lianne ^a   Westerholz, Sören ^a   Namendorf, Christian ^a   Gerlach, Tamara ^a   Uhr, Manfred ^a   Chen, Alon ^a   Deussing, Jan M ^a   Holsboer, Florian ^a   Hausch, Felix ^a   Schmidt, Mathias V ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Lead Discovery Center GmbH   (Germany)

Author keywords

Amygdala; Antidepressants; Anxiety; FKBP51; PTSD

Indexed keywords

ANXIOLYTIC AGENT; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 51; LIGAND 2; MESSENGER RNA; PARVOVIRUS VECTOR; SAFIT 2; UNCLASSIFIED DRUG; LIGAND; TACROLIMUS BINDING PROTEIN 5;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOLATERAL AMYGDALA; BRAIN TISSUE; CANNULA; CENTRAL NUCLEUS (AMYGDALA); CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; FORCED SWIM TEST; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MICROINJECTION; MOUSE; NONHUMAN; OPEN FIELD TEST; PHARMACOLOGICAL BLOCKING; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RISK FACTOR; TRANQUILIZING ACTIVITY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANXIETY; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; DRUG THERAPY; METABOLISM; PROCEDURES; PSYCHOLOGY;

AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; LIGANDS; MALE; MICE; MICE, INBRED C57BL; MICROINJECTIONS; RISK FACTORS; TACROLIMUS BINDING PROTEINS;

EID: 84931345970     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4024-14.2015     Document Type: Article

References (53)

1. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, Stender J, Barnow S, John U, Teumer A, Biffar R, Nauck M, Völzke H, Freyberger HJ, Grabe HJ (2011) Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 36:1982–1991.
2. Attwood BK, Bourgognon JM, Patel S, Mucha M, Schiavon E, Skrzypiec AE, Young KW, Shiosaka S, Korostynski M, Piechota M, Przewlocki R, Pawlak R (2011) Neuropsin cleaves EphB2 in the amygdala to control anxiety. Nature 473:372–375.
3. Binder EB (2009) The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34:S186 –S195.
4. Binder EB, Holsboer F (2006) Pharmacogenomics and antidepressant drugs. Ann Med 38:82–94.
5. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Künzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, et al. (2004) Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319 –1325.
6. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF, Ressler KJ (2008) Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299:1291–1305.
7. Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N, Vitiello B, Birmaher B, Mayes T, Zelazny J, Onorato M, Devlin B, Clarke G, DeBar L, Keller M (2010) Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. Am J Psychiatry 167:190 –197.
8. Chrousos GP (2009) Stress and disorders of the stress system. Nat Rev Endocrinol 5:374 –381.
9. Davis M (1994) The role of the amygdala in emotional learning. Int Rev Neurobiol 36:225–266.
10. Dias BG, Banerjee SB, Goodman JV, Ressler KJ (2013) Towards new approaches to disorders of fear and anxiety. Curr Opin Neurobiol 23:346–352.
11. Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213:93–118.
12. Ellsworth KA, Moon I, Eckloff BW, Fridley BL, Jenkins GD, Batzler A, Biernacka JM, Abo R, Brisbin A, Ji Y, Hebbring S, Wieben ED, Mrazek DA, Weinshilboum RM, Wang L (2013) FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet Genomics 23:156 –166.
13. Etkin A, Wager TD (2007) Functional neuroimaging of anxiety: a metaanalysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 164:1476 –1488.
14. Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P, Sippel C, Zannas AS, Draenert R, Binder EB, Almeida OF, Rühter G, Uhr M, Schmidt MV, Touma C, Bracher A, Hausch F (2015) Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol 11:33–37.
15. Gopalakrishnan R, Kozany C, Gaali S, Kress C, Hoogeland B, Bracher A, Hausch F (2012a) Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52. J Med Chem 55:4114–4122.
16. Gopalakrishnan R, Kozany C, Wang Y, Schneider S, Hoogeland B, Bracher A, Hausch F (2012b) Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52. J Med Chem 55:4123– 4131.
17. Gray TS (1993) Amygdaloid CRF pathways: role in autonomic, neuroendocrine, and behavioral responses to stress. Ann N Y Acad Sci 697:53– 60.
18. Hartmann J, Wagner KV, Dedic N, Marinescu D, Scharf SH, Wang XD, Deussing JM, Hausch F, Rein T, Schmidt U, Holsboer F, Mu¨ller MB, Schmidt MV (2012a) Fkbp52 heterozygosity alters behavioral, endocrine and neurogenetic parameters under basal and chronic stress conditions in mice. Psychoneuroendocrinology 37:2009 –2021.
19. Hartmann J, Wagner KV, Liebl C, Scharf SH, Wang XD, Wolf M, Hausch F, Rein T, Schmidt U, Touma C, Cheung-Flynn J, Cox MB, Smith DF, Holsboer F, Mu¨ller MB, Schmidt MV (2012b) The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress. Neuropharmacology 62:332–339.
20. Holsboer F (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477–501.
21. Holz NE, Buchmann AF, Boecker R, Blomeyer D, Baumeister S, Wolf I, Rietschel M, Witt SH, Plichta MM, Meyer-Lindenberg A, Banaschewski T, Brandeis D, Laucht M (2015) Role of FKBP5 in emotion processing: results on amygdala activity, connectivity and volume. Brain Struct Funct 220:1355–1368.
22. Joels M, Baram TZ (2009) The neuro-symphony of stress. Nat Rev Neurosci 10:459–466.
23. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM, Pace TW, Mercer KB, Mayberg HS, Bradley B, Nemeroff CB, Holsboer F, Heim CM, Ressler KJ, Rein T, Binder EB (2013) Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 16:33– 41.
24. Koenen KC, Saxe G, Purcell S, Smoller JW, Bartholomew D, Miller A, Hall E, Kaplow J, Bosquet M, Moulton S, Baldwin C (2005) Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Mol Psychiatry 10:1058 –1059.
25. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894 –902.
26. Lavebratt C, Aberg E, Sjöholm LK, Forsell Y (2010) Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 125:249 –255.
27. LeDoux J (2007) The amygdala. Curr Biol 17:R868 –R874.
28. Lupien SJ, McEwen BS, Gunnar MR, Heim C (2009) Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 10:434–445.
29. McEwen BS, Sapolsky RM (1995) Stress and cognitive function. Curr Opin Neurobiol 5:205–216.
30. Mehta D, Gonik M, Klengel T, Rex-Haffner M, Menke A, Rubel J, Mercer KB, Pütz B, Bradley B, Holsboer F, Ressler KJ, Müller-Myhsok B, Binder EB (2011) Using polymorphisms in FKBP5 to define biologically distinct subtypes of posttraumatic stress disorder: evidence from endocrine and gene expression studies. Arch Gen Psychiatry 68:901–910.
31. Menke A, Klengel T, Rubel J, Brückl T, Pfister H, Lucae S, Uhr M, Holsboer F, Binder EB (2013) Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav 12:289 –296.
32. Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161–1169.
33. Pariante CM, Miller AH (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391–404.
34. Pérez-Ortiz JM, García-Gutiérrez MS, Navarrete F, Giner S, Manzanares J (2013) Gene and protein alterations of FKBP5 and glucocorticoid receptor in the amygdala of suicide victims. Psychoneuroendocrinology 38: 1251–1258.
35. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A (2011) Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 36:87–113.
36. Quinta´ HR, Maschi D, Gomez-Sanchez C, Piwien-Pilipuk G, Galigniana MD (2010) Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth. J Neurochem 115:716 –734.
37. Riggs DL, Roberts PJ, Chirillo SC, Cheung-Flynn J, Prapapanich V, Ratajczak T, Gaber R, Picard D, Smith DF (2003) The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J 22:1158 –1167.
38. Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA (2010) Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 35:1674 –1683.
39. Scharf SH, Liebl C, Binder EB, Schmidt MV, Müller MB (2011) Expression and regulation of the Fkbp5 gene in the adult mouse brain. PloS One 6:e16883.
40. Schmidt MV, Sterlemann V, Ganea K, Liebl C, Alam S, Harbich D, Greetfeld M, Uhr M, Holsboer F, Müller MB (2007) Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology 32:417– 429.
41. Schmidt MV, Schülke JP, Liebl C, Stiess M, Avrabos C, Bock J, Wochnik GM, Davies HA, Zimmermann N, Scharf SH, Trümbach D, Wurst W, Zieglgänsberger W, Turck C, Holsboer F, Stewart MG, Bradke F, Eder M, Müller MB, Rein T (2011) Tumor suppressor down-regulated in renal cell carcinoma 1 (DRR1) is a stress-induced actin bundling factor that modulates synaptic efficacy and cognition. Proc Natl Acad Sci U S A 108: 17213–17218.
42. Schmidt MV, Paez-Pereda M, Holsboer F, Hausch F (2012) The prospect of FKBP51 as a drug target. ChemMedChem 7:1351–1359.
43. Shin LM, Liberzon I (2010) The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology 35:169 –191.
44. Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME (2007) Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 61:198 –209.
45. Supriyanto I, Sasada T, Fukutake M, Asano M, Ueno Y, Nagasaki Y, Shirakawa O, Hishimoto A (2011) Association of FKBP5 gene haplotypes with completed suicide in the Japanese population. Prog Neuropsychopharmacol Biol Psychiatry 35:252–256.
46. Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G, Chana G, Soontornniyomkij V, Achim CL, HIV Neurobehavioral Research Center (2009) Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 4:218 –226.
47. Tennant C (2001) Work-related stress and depressive disorders. J Psychosom Res 51:697–704.
48. Thase ME (2006) Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 11:12–21.
49. Wang XD, Chen Y, Wolf M, Wagner KV, Liebl C, Scharf SH, Harbich D, Mayer B, Wurst W, Holsboer F, Deussing JM, Baram TZ, Müller MB, Schmidt MV (2011) Forebrain CRHR1 deficiency attenuates chronic stress-induced cognitive deficits and dendritic remodeling. Neurobiol Dis 42:300 –310.
50. Willour VL, Chen H, Toolan J, Belmonte P, Cutler DJ, Goes FS, Zandi PP, Lee RS, MacKinnon DF, Mondimore FM, Schweizer B, Bipolar Disorder Phenome Group, NIMH Genetics Initiative Bipolar Disorder Consortium
51. DePaulo JR Jr, Gershon ES, McMahon FJ, Potash JB (2009) Familybased association of FKBP5 in bipolar disorder. Mol Psychiatry 14:261–268.
52. Wochnik GM, Rüegg J, Abel GA, Schmidt U, Holsboer F, Rein T (2005) FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 280:4609–4616.
53. Yehuda R (2009) Status of glucocorticoid alterations in post-traumatic stress disorder. Ann N Y Acad Sci 1179:56–69.